4.5 Article

PREGABALIN ENHANCES MYELIN REPAIR AND ATTENUATES GLIAL ACTIVATION IN LYSOLECITHIN-INDUCED DEMYELINATION MODEL OF RAT OPTIC CHIASM

Journal

NEUROSCIENCE
Volume 344, Issue -, Pages 148-156

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2016.12.037

Keywords

multiple sclerosis; optic chiasm; lysolecithin; pregabalin; myelin repair; glial activation

Categories

Funding

  1. Neuroscience Research Center
  2. Babol University of Medical Sciences, Babol, Mazandaran, Iran

Ask authors/readers for more resources

Multiple sclerosis (MS) is an autoimmune disease in which more than 70% of patients experience visual disturbance as the earliest symptoms. Lysolecithin (LPC)-induced focal demyelination model has been developed to evaluate the effects of different therapies on myelin repair improvement. In this study, the effects of pregabalin administration on myelin repair and glial activation were investigated. Local demyelination was induced by administration of LPC (1%, 2 mu L) into the rat optic chiasm. Rats underwent daily injection of pregabalin (30 mg/kg, i.p) or vehicle. Visual-evoked potentials (VEPs) recordings were performed for evaluating the function of optic pathway on days 3, 7, 14 and 28 post lesions. Myelin specific staining and immunostaining against GFAP and lba1 were also carried out for assessment of myelination and glial activation respectively. Electrophysiological data indicated that pregabalin administration could significantly reduce the P1-N1 latency and increase the amplitude of VEPs waves compared to saline group. Luxol fast blue staining and immunostaining against PLP, as mature myelin marker, showed that myelin repair was improved in animals received pregabalin treatment. In addition, pregabalin effectively reduced the expression of GFAP and lba1 as activated glial markers in optic chiasm. The present study indicates that pregabalin administration enhances myelin repair and ameliorates glial activation of optic chiasm following local injection of LPC. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available